NEW YORK (GenomeWeb) — CRISPR-based therapeutics developer Editas Medicine has agreed to provide up to $125 million in research funding to the Broad Institute in exchange for the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.